A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation.
J Interv Card Electrophysiol
; 9(2): 215-22, 2003 Oct.
Article
en En
| MEDLINE
| ID: mdl-14574034
ABSTRACT
Clinical trials assessing the efficacy of anti- arrhythmic drugs for terminating atrial fibrillation have demonstrated that rate control drugs have little to no added efficacy compared to placebo; however, spontaneous conversion of recent-onset atrial fibrillation is common. Antiarrhythmic drugs such as oral dofetilide, oral bolus-flecainide and propafenone and intravenous ibutilide all have a role in terminating atrial fibrillation. Active comparator trials have demonstrated that amiodarone is more efficacious in maintaining sinus rhythm than propafenone and sotalol. Multiple trials have demonstrated the safety of amiodarone, sotalol, dofetilide and azimilide in a post-myocardial infarction population and amiodarone and dofetilide in a congestive heart failure population. Newer antiarrhythmic agents, some with novel mechanisms of action, will add to the pharmacologic armamentarium in treating atrial fibrillation.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Fibrilación Atrial
/
Ensayos Clínicos como Asunto
/
Antiarrítmicos
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
J Interv Card Electrophysiol
Asunto de la revista:
CARDIOLOGIA
Año:
2003
Tipo del documento:
Article
País de afiliación:
Estados Unidos